Journal of Neural Transmission

, Volume 118, Issue 4, pp 539–543 | Cite as

Is C-reactive protein level a marker of advanced motor and neuropsychiatric complications in Parkinson’s disease?

  • Sharon Hassin-Baer
  • Oren S. Cohen
  • Eli Vakil
  • Noa Molshazki
  • Ben-Ami Sela
  • Zeev Nitsan
  • Joab Chapman
  • David Tanne
Movement Disorders - Original Article
First Online:
Received:
Accepted:

Abstract

C-reactive protein (CRP) is a plasma protein involved in inflammation. While its levels have been associated with stroke, cognitive impairment and depression, the association with clinical characteristics of Parkinson’s disease (PD) is unknown. A total of 73 consecutive patients with PD (46 males, age 68.8 ± 11.5 years) were evaluated regarding motor as well as cognitive and psychiatric features of PD. Plasma CRP levels were determined and tests for associations with disease parameters were performed. The average level of CRP was 3.9 ± 4.1 μmol/L, and 45.2% of the patients (n = 33) had a level above 3.0 μmol/L. Patients in the high CRP group tended to be older (71.4 ± 9.2 vs. 66.7 ± 12.9 years; p = 0.08) and coronary artery disease (CAD) was more common (36 vs. 10%, p < 0.05) in the high CRP group, but no differences were found between the groups regarding gender, disease duration, levodopa dose, motor scores or most of the neuropsychiatric complications such as severity of depression, psychosis, dementia, cognitive decline or frontal lobe dysfunction. Reported depression (at present or in the past) was more common in the high CRP group (54.5 vs. 25%, p = 0.01). CRP levels in patients with PD are associated with a higher prevalence of CAD, but are not associated with PD duration or severity, or with neuropsychiatric complications other than reported depression.

Keywords

Parkinson’s disease Inflammation C-reactive protein Risk factor Neuropsychiatric complications 
This is a preview of subscription content, log in to check access.

References

  1. Berk M, Wadee AA, Kuschke RH, O’Neill-Kerr A (1997) Acute phase proteins in major depression. J Psychosom Res 43:529–534PubMedCrossRefGoogle Scholar
  2. Chen H, O’Reilly EJ, Schwarzschild MA, Ascherio A (2008) Peripheral inflammatory biomarkers and risk of Parkinson’s disease. Am J Epidemiol 167(1):90–95PubMedCrossRefGoogle Scholar
  3. Cicchetti F, Brownell AL, Williams K, Chen YI, Livni E, Isacson O (2002) Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 15:991–998PubMedCrossRefGoogle Scholar
  4. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson’s disease. Neuroscience 52:1–6PubMedCrossRefGoogle Scholar
  5. Dubois B, Slachevsky A, Litvan I, Pillon B (2000) The FAB: a frontal assessment battery at bedside. Neurology 55:1621–1626PubMedGoogle Scholar
  6. Duong T, Nikolaeva M, Acton PJ (1997) C-reactive protein-like immunoreactivity in the neurofibrillary tangles of Alzheimer’s disease. Brain Res 749:152–156PubMedCrossRefGoogle Scholar
  7. Duong T, Acton PJ, Johnson RA (1998) The in vitro neuronal toxicity of pentraxins associated with Alzheimer’s disease brain lesions. Brain Res 813:303–312PubMedCrossRefGoogle Scholar
  8. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198PubMedCrossRefGoogle Scholar
  9. Friedberg G, Zoldan J, Weizman A, Melamed E (1998) Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson’s disease. Clin Neuropharmacol 21:280–284PubMedGoogle Scholar
  10. Greenamyre JT, MacKenzie G, Peng TI, Stephans SE (1999) Mitochondrial dysfunction in Parkinson’s disease. Biochem Soc Symp 66:85–97PubMedGoogle Scholar
  11. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397PubMedCrossRefGoogle Scholar
  12. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
  13. Iwamoto N, Nishiyama E, Ohwada J, Arai H (1994) Demonstration of CRP immunoreactivity in brains of Alzheimer’s disease: immunohistochemical study using formic acid pretreatment of tissue sections. Neurosci Lett 177:23–26PubMedCrossRefGoogle Scholar
  14. Kuo HK, Yen CJ, Chang CH, Kuo CK, Chen JH, Sorond F (2005) Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol 4:371–380Google Scholar
  15. Leentjens AF, Verhey FR, Luijckx GJ, Troost J (2000) The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson’s disease. Mov Disord 15:1221–1224PubMedCrossRefGoogle Scholar
  16. Lezak M (1995) Neuropsychological assessment, 3rd edn. Oxford University Press, New YorkGoogle Scholar
  17. Litvan I, Chesselet MF, Gasser T, Di Monte DA, Parker D Jr, Hagg T, Hardy J, Jenner P, Myers RH, Price D, Hallett M, Langston WJ, Lang AE, Halliday G, Rocca W, Duyckaerts C, Dickson DW, Ben-Shlomo Y, Goetz CG, Melamed E (2007) The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol 66(5):329–336PubMedCrossRefGoogle Scholar
  18. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291PubMedGoogle Scholar
  19. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA (2002) Clinical depression and inflammatory risk markers for coronary heart disease. Am J Cardiol 90:1279–1283PubMedCrossRefGoogle Scholar
  20. Nagatsu T, Sawada M (2005) Inflammatory process in Parkinson’s disease: role for cytokines. Curr Pharm Des 11:999–1016PubMedCrossRefGoogle Scholar
  21. Paul A, Ko KW, Li L, Yechoor V, McCrory MA, Szalai AJ, Chan L (2004) C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109:647–655PubMedCrossRefGoogle Scholar
  22. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107:499–511PubMedCrossRefGoogle Scholar
  23. Silverman JM, Beeri MS, Schmeidler J, Rosendorff C, Angelo G, Mavris RS, Grossman HT, Elder GA, Carrion-Baralt J, West R (2009) C-reactive protein and memory function suggest antagonistic pleiotropy in very old nondemented subjects. Age Ageing 38(2):237–241PubMedCrossRefGoogle Scholar
  24. Song IU, Kim JS, Chung SW, Lee KS (2009) Is there an association between the level of high-sensitivity C-reactive protein and idiopathic Parkinson’s disease? A comparison of Parkinson’s disease patients, disease controls and healthy individuals. Eur Neurol 62(2):99–104PubMedCrossRefGoogle Scholar
  25. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S, Vila M, Jackson-Lewis V, Przedborski S (2003) Cyclooxygenase-2 is instrumental in Parkinson’s disease neurodegeneration. Proc Natl Acad Sci USA 100:5473–5478PubMedCrossRefGoogle Scholar
  26. Vakil E, Blachstein H (1997) Rey AVLT: developmental norms for adults and the sensitivity of different memory measures to age. Clin Neuropsychol 11:345–355CrossRefGoogle Scholar
  27. Wechsler D (1997) Wechsler Memory Scale, 3rd edn. Psychological Corporation, San AntonioGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Sharon Hassin-Baer
    • 1
    • 2
    • 3
    • 6
  • Oren S. Cohen
    • 1
    • 2
    • 3
    • 6
  • Eli Vakil
    • 7
  • Noa Molshazki
    • 3
    • 6
  • Ben-Ami Sela
    • 4
    • 6
  • Zeev Nitsan
    • 1
    • 2
    • 3
  • Joab Chapman
    • 1
    • 3
    • 6
  • David Tanne
    • 1
    • 3
    • 5
    • 6
  1. 1.Department of NeurologyChaim Sheba Medical CenterTel HashomerIsrael
  2. 2.Parkinson’s Disease and Movement Disorders ClinicChaim Sheba Medical CenterTel HashomerIsrael
  3. 3.Sagol Neuroscience Center, Chaim Sheba Medical CenterTel HashomerIsrael
  4. 4.Institute of Chemical PathologyChaim Sheba Medical CenterTel HashomerIsrael
  5. 5.Stroke Center, Chaim Sheba Medical CenterTel HashomerIsrael
  6. 6.Affiliated to Sackler School of Medicine, Tel Aviv UniversityTel AvivIsrael
  7. 7.Department of PsychologyBar Ilan UniversityRamat-GanIsrael

Personalised recommendations